The 2026 Demirtaş review in International Journal of Molecular Sciences (doi:10.3390/ijms27188344) grades BPC-157's rodent IRI evidence as mechanistically coherent but structurally deficient. Every included study is non-GLP, rodent-only, and originates from a narrow authorship cluster. The review identifies oxidative stress attenuation, NO-pathway modulation, and endothelial stabilisation as its mechanistic pillars — while flagging absent independent replication as the structural weakness.
What Scope and Methodology Does the Demirtaş 2026 Review Apply to the BPC-157 IRI Literature?
The Demirtaş 2026 IJMS review is a critical narrative review — not a PRISMA-compliant systematic review — covering rodent IRI and reperfusion-associated vascular injury models across skeletal muscle, liver, kidney, and lung. It applies a qualitative mechanistic coherence framework rather than formal risk-of-bias instruments, asking whether reported findings are consistent with BPC-157's established signalling biology.
A critical narrative review does not apply pre-registered inclusion/exclusion criteria, does not calculate pooled effect sizes, and does not formally assess risk of bias using validated instruments such as SYRCLE or CAMARADES. The Demirtaş review instead evaluates whether study designs are sufficient to attribute observed effects to the peptide rather than to non-specific surgical or anaesthetic confounders.
The review's primary source base is anchored in two Demirtaş-authored experimental studies: a 2025 Medicine paper (PMC11857380) on distant organ protection in lower-extremity IRI, and a 2026 Scientific Reports study (doi:10.1038/s41598-026-55449-1) on skeletal muscle IRI. These are supplemented by earlier Sikiric-group studies and the Hsieh et al. 2017 VEGFR2 mechanistic paper (PMID 27847966).
The concentration of primary sources within a small authorship cluster is noted by the review itself as a limitation. The reviewer's dual role — as both the critical reviewer and the author of two primary experimental studies under review — is a conflict-of-interest consideration that the review does not explicitly address.
What Three Mechanistic Pillars Does the Review Identify as the Evidential Core for BPC-157 in IRI?
The Demirtaş 2026 review organises BPC-157's IRI evidence around three mechanistic pillars: oxidative stress attenuation via endogenous antioxidant enzyme upregulation; nitric oxide pathway modulation through preferential eNOS over iNOS activity; and endothelial stabilisation via VEGFR2–Akt signalling and angiopoietin-1 co-expression. Evidence strength differs substantially across the three pillars.
The oxidative stress pillar carries the strongest experimental support within the IRI-specific literature. Reductions in malondialdehyde (MDA) and restoration of superoxide dismutase (SOD) and catalase activity are reported consistently across the reviewed studies. These are biochemically straightforward assays with established reference ranges, making cross-study comparison more reliable than for the molecular signalling endpoints.
The NO-pathway pillar rests on a mechanistic inference rather than direct IRI-model measurement. The eNOS/iNOS selectivity hypothesis — that BPC-157 preferentially upregulates vasoprotective eNOS-derived NO while suppressing pathological iNOS-derived peroxynitrite — is plausible given the peptide's VEGFR2–Akt–eNOS signalling characterisation by Hsieh et al. (2017). However, no IRI-specific study in the reviewed corpus directly measured eNOS and iNOS protein expression simultaneously.
The endothelial stabilisation pillar draws on the Yıldırım 2026 angiopoietin-1 immunostaining data and the Hsieh 2017 VEGFR2 upregulation findings. The Demirtaş review correctly notes that VEGF-driven angiogenesis is not the operative acute mechanism in short-duration IRI models. The proposed mechanism is instead VEGFR2-mediated endothelial survival signalling, which is mechanistically distinct from angiogenesis and more temporally compatible with the IRI model timeframe.
How Does the Review Grade the Oxidative Stress Evidence Specifically?
Within the oxidative stress pillar, the Demirtaş review grades MDA and SOD data as the most internally consistent findings in the BPC-157 IRI corpus. Both markers are measured by established colorimetric assays, reported across multiple studies, and directionally uniform. The review notes that no study validated its assay against a certified reference standard — a qualification that limits inter-laboratory comparability.
MDA is generated by the non-enzymatic decomposition of polyunsaturated fatty acid hydroperoxides during oxidative stress. Its tissue concentration is a surrogate for the magnitude of lipid peroxidation during the reperfusion burst. In the reviewed IRI studies, BPC-157-treated animals consistently showed lower tissue MDA concentrations than untreated IRI controls, with the effect present in both primary ischaemic tissue and distant organs.
SOD activity restoration is the complementary finding: IRI-induced depletion of SOD was attenuated in BPC-157-treated animals. The review notes that this pattern is consistent with BPC-157 acting upstream of antioxidant enzyme expression rather than as a direct free-radical scavenger. The distinction matters mechanistically — a direct scavenger would be consumed stoichiometrically, while an upstream regulator would preserve enzymatic capacity across the reperfusion period.
What Does the Review Conclude About the Apoptosis Signalling Evidence?
The review treats apoptosis signalling evidence — reduced caspase-3 activity, lower BAX/BCL-2 ratios, and decreased TUNEL-positive cell counts — as directionally supportive but methodologically weaker than the oxidative stress data. Immunohistochemistry-based caspase-3 quantification is semi-quantitative and observer-dependent; no study employed flow cytometry or validated ELISA-based caspase activity assays as a confirmatory method.
Caspase-3 is the terminal executioner protease in the intrinsic apoptotic cascade, activated when mitochondrial permeability transition releases cytochrome c during reperfusion. The Yıldırım 2026 study reported reduced caspase-3 immunostaining in gastrocnemius muscle sections from BPC-157-treated rats. The upstream mechanistic proposal — Akt phosphorylation suppressing BAX transcription — is consistent with the VEGFR2–Akt pathway but was not directly measured in the IRI study design.
The BAX/BCL-2 ratio was reported as reduced in BPC-157-treated animals in the Demirtaş 2025 distant-organ study, extending the anti-apoptotic signal to liver and kidney tissue. The review flags that BAX and BCL-2 protein quantification by Western blot is subject to loading control variability and does not distinguish between transcriptional and post-translational regulation.
How Does the Review Assess the Inflammatory Marker Evidence?
Inflammatory marker data — reduced TNF-α, IL-6, and myeloperoxidase (MPO) activity in BPC-157-treated IRI animals — are assessed as consistent with the peptide's broader anti-inflammatory profile but limited by the absence of time-course measurements. All reviewed studies report single post-reperfusion timepoints, preventing characterisation of whether BPC-157 modifies inflammatory kinetics or merely magnitude at a fixed endpoint.
MPO activity is a validated surrogate for neutrophil infiltration into tissue. Its reduction in BPC-157-treated animals across both primary ischaemic and distant organ sites is one of the more clinically interpretable findings in the reviewed corpus, because neutrophil-mediated tissue destruction is a well-characterised IRI mechanism. The Demirtaş 2025 study reported significantly lower hepatic and renal MPO activity in treated rats, with effect sizes the review describes as biologically meaningful.
TNF-α and IL-6 measurements were obtained by ELISA from tissue homogenates. Tissue cytokine concentrations from homogenates reflect a composite of local production, systemic spillover, and cellular sequestration — a methodological limitation shared with most rodent IRI cytokine studies. Plasma cytokine time-course data, which would better characterise the systemic inflammatory response, were not reported in any reviewed study.
What Specific Study Design Deficiencies Does the Review Identify as Most Consequential?
The Demirtaş 2026 review identifies three study design deficiencies as most consequential: the absence of blinded outcome assessment, the use of intraperitoneal administration with no clinical equivalent, and the failure to include sham-operated control groups uniformly across all studies. Each introduces a specific bias vector that could independently account for the reported treatment effects.
Unblinded outcome assessment is the most pervasive bias risk in the reviewed corpus. Histopathological scoring, immunohistochemistry quantification, and biochemical assay interpretation can all be influenced by assessor knowledge of treatment allocation. The reviewed studies do not report blinding procedures for outcome assessors, and the review does not claim they were blinded — leaving performance and detection bias unexcluded.
Intraperitoneal administration — the predominant route in the reviewed studies — has no clinical equivalent for IRI indications. The pharmacokinetically relevant question — what systemic exposure is achieved at the time of reperfusion — cannot be answered from the available data, because no IRI study measured plasma BPC-157 concentrations at any timepoint.
The absence of a consistent sham-operated control group in some reviewed studies means that baseline injury attributable to the surgical procedure itself cannot be separated from IRI-specific injury. This is a standard rodent IRI design requirement that was not uniformly met across the reviewed corpus.
Why Does the Single-Laboratory Concentration of BPC-157 IRI Evidence Matter for Evidence Grading?
The BPC-157 IRI evidence base is concentrated within a small number of research groups with overlapping authorship. Independent replication by laboratories with no prior BPC-157 publication history has not occurred for any IRI-specific finding. This concentration raises the prior probability of confirmation bias and leaves uniformly large reported effect sizes untested against independent replication regression-to-the-mean.
Single-laboratory concentration is a recognised problem in preclinical pharmacology broadly. The reproducibility crisis literature documents that effect sizes reported by originating laboratories are systematically larger than those obtained by independent replicators. For BPC-157 IRI specifically, the absence of any independent replication attempt means the reported effect sizes — uniformly large and statistically significant — have not been stress-tested against the regression-to-the-mean that typically occurs in replication studies.
The reviewer's dual role — as both the critical reviewer and the author of two primary experimental studies under review — is a conflict-of-interest consideration that the review does not explicitly address. This does not disqualify the review's analytical framework, but it is relevant context for researchers assessing the objectivity of the evidence grading applied to the Demirtaş 2025 and 2026 experimental studies specifically.
What Does the Demirtaş 2026 Review Ultimately Conclude About the Sufficiency of the IRI Evidence?
The Demirtaş 2026 review concludes that BPC-157's rodent IRI evidence is mechanistically coherent and directionally consistent across organ systems, but insufficient to support clinical translation. It calls for independent replication, GLP-compliant designs, validated pharmacokinetic characterisation, and receptor identification as prerequisites — conclusions that align with the Mateescu et al. 2026 Pharmaceutics critique of BPC-157's broader development programme.
The review's conclusion that the evidence is "mechanistically coherent" is a qualified endorsement: it means the observed effects are consistent with BPC-157's known biology, not that the effects are proven. Mechanistic coherence is a necessary but not sufficient condition for translational confidence. The Demirtaş review does not claim the IRI evidence meets any regulatory evidentiary threshold, and its framing is explicitly preclinical throughout.
For researchers cross-referencing this evidence against the broader BPC-157 development landscape, the Mateescu 2026 Pharmaceutics review's conclusion that BPC-157 lacks a validated analytical method applies directly to any proposed IRI-indication IND-enabling programme. The IRI evidence, however mechanistically interesting, sits downstream of a more fundamental development bottleneck that the Demirtaş review does not address. How Does the 2026 Demirtaş Critical Review Grade the Preclinical Evidence for BPC-157 in Rodent Ischemia–Reperfusion Injury — and What Should Performance Practitioners Actually Conclude? What Does 2026 Research Reveal About BPC-157's Mechanisms in Rodent Ischemia–Reperfusion Injury — and What Are the Metabolic Performance Implications? How Do BPC-157's 2026 Rodent IRI Redox Biomarker Numbers Compare to Exercise-Induced Oxidative Stress Magnitudes — and What Does That Gap Mean for Performance Practitioners?